| pubmed-article:7581089 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7581089 | lifeskim:mentions | umls-concept:C0024305 | lld:lifeskim |
| pubmed-article:7581089 | lifeskim:mentions | umls-concept:C1268930 | lld:lifeskim |
| pubmed-article:7581089 | lifeskim:mentions | umls-concept:C2004454 | lld:lifeskim |
| pubmed-article:7581089 | lifeskim:mentions | umls-concept:C0242602 | lld:lifeskim |
| pubmed-article:7581089 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:7581089 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7581089 | pubmed:dateCreated | 1995-12-12 | lld:pubmed |
| pubmed-article:7581089 | pubmed:abstractText | Chemotherapy induces high remission rates in high-grade lymphoma. However relapse remains a major problem. One approach to this is myeloablative chemotherapy with transplantation of autologous bone marrow or peripheral blood progenitor cells (PBPC). Immunological mechanisms have been suggested to play a role in the prevention of relapse after transplantation. We investigated the recovery of cellular immune functions after high-dose chemotherapy and PBPC transplantation in 5 patients with high grade non-Hodgkin's lymphoma. All patients showed rapid reconstitution of natural killer (NK) and inducible lymphokine-activated killer (LAK)-activity 10-14 days after transplantation. Four of 5 patients showed higher levels of LAK-generation in the post-transplant period compared with levels prior to myeloablative treatment. Absolute lymphocyte counts in peripheral blood reached 1.0 x 10(9)/l between days 10 and 13 with a predominance of CD8+ cells and an inversion of the CD4/CD8 ratio. Four of 5 patients had a transient increase in CD56+ and CD16+ cell counts post-transplant. No change in the proportion of CD25+ cells was noted. These results show that PBPC transplantation leads to a rapid recovery of cellular immune functions after myeloablative chemotherapy and provides evidence for an increased presence of LAK precursor cells early in the post-transplant period which can be activated by IL-2 to exert high levels of cytotoxicity. | lld:pubmed |
| pubmed-article:7581089 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7581089 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7581089 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7581089 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:7581089 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:CrowtherDD | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:SternP LPL | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:RadfordJ AJA | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:ScheitSS | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:PettengellRR | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:MorgensternG... | lld:pubmed |
| pubmed-article:7581089 | pubmed:author | pubmed-author:GhielminiMM | lld:pubmed |
| pubmed-article:7581089 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7581089 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:7581089 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7581089 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7581089 | pubmed:pagination | 901-6 | lld:pubmed |
| pubmed-article:7581089 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:meshHeading | pubmed-meshheading:7581089-... | lld:pubmed |
| pubmed-article:7581089 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7581089 | pubmed:articleTitle | Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:7581089 | pubmed:affiliation | CRC Department of Immunology, Paterson Institute for Cancer Research, Manchester, UK. | lld:pubmed |
| pubmed-article:7581089 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7581089 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
